The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention with drug-eluting stents, according to a recent multicenter study published in the Journal of the American Medical Association.
The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction (MI), or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention (PCI) with drug-eluting stents, according to a recent multicenter study published in the March 16, 2011, issue of the Journal of the American Medical Association.
Researchers compared high-dose clopidogrel (600-mg initial dose, 150-mg thereafter) with standard-dose clopidogrel (no additional loading dose, 75-mg daily) for 6 months in 2,214 patients participating in the Gauging Responsiveness with A VerifyNow assay -Impact on Thrombosis And Safety (GRAVITAS) study. The patients had high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents.
At 6 months, 25 of 1,109 patients (2.3%) receiving high-dose clopidogrel compared with 25 of 1,105 patients (2.3%) receiving standard-dose clopidogrel died from cardiovascular causes, had a nonfatal MI, or had stent thrombosis. High-dose clopidogrel provided a 22% absolute reduction in the rate of high on-treatment reactivity at 30 days compared with standard-dose treatment. In addition, severe or moderate bleeding was not associated with the high-dose regimen.
"The results of GRAVITAS do not support a uniform treatment strategy of high-dose clopidogrel in patients with high on-treatment reactivity identified by a single platelet function test after PCI," concluded the researchers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More